Linoladiol-H N

Estradiol hemihydrate, the active ingredient in Linoladiol-H N, is a synthetic estrogen presented as a cutaneous formulation for topical use. It is combined with prednisolone sesquihydrate, a glucocorticoid, to address hormone‑related and inflammatory skin conditions in adult patients.

GNH USA supplies Linoladiol-H N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under GMP conditions.

Linoladiol-H N combines an estrogen and a corticosteroid and is used for cutaneous conditions involving hormonal imbalance or inflammation. - Atrophic skin: promotes tissue regeneration and reduces thinning. - Psoriasis: decreases inflammation and scaling. - Post‑menopausal vulvovaginal atrophy: improves mucosal integrity and comfort.

Common Side Effects: - Skin irritation or erythema at the application site. - Mild itching or burning sensation. - Localized dryness or peeling. - Temporary hyperpigmentation. - Minor hormonal effects such as breast tenderness. - Transient increase in local blood flow.

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, anaphylaxis). - Significant skin atrophy or striae. - Systemic glucocorticoid effects (elevated blood glucose, hypertension) with extensive use. - Hormone‑related thromboembolic events. - Secondary infection of the treated area. - Persistent ulceration or necrosis.

Before using Linoladiol-H N, consider the following precautions: - Assess for known hypersensitivity to estrogen or corticosteroids: avoid use if allergy is present. - Evaluate skin integrity: do not apply on infected, broken, or ulcerated skin. - Monitor for systemic hormonal effects: prolonged large‑area use may affect endocrine balance. - Use the lowest effective amount for the shortest duration to minimize skin atrophy. - Caution in patients with diabetes or hypertension: observe for systemic glucocorticoid impact. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Linoladiol-H N may interact with other systemic medications. Consider the following: Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic corticosteroid exposure. - Oral anticoagulants (e.g., warfarin): estrogen component can enhance clotting risk. - Antidiabetic agents: systemic absorption of corticosteroid may raise blood glucose levels.

Moderate Interactions (Monitor Closely): - Other topical steroids: risk of additive skin thinning. - Hormonal contraceptives: potential for altered estrogen metabolism. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for gastrointestinal irritation when systemic absorption occurs.